...
首页> 外文期刊>The New Microbiologica >Combination of thioridazine and dicloxacillin as a possible treatment strategy of staphylococci
【24h】

Combination of thioridazine and dicloxacillin as a possible treatment strategy of staphylococci

机译:硫利达嗪和双氯西林联合作为葡萄球菌的可能治疗策略

获取原文
获取原文并翻译 | 示例
           

摘要

We have previously shown that the phenothiazine, thioridazine, acts in synergy with the beta-lactam antibiotic, dicloxacillin, to kill methicillin-resistant Staphylococcus aureus. In this study, we investigated whether synergy by combining these two drugs could also be observed in vancomycin intermediate susceptible S. aureus (VISA) and methicillin-resistant Staphylococcus epidermidis (MRSE). Synergy was observed in three of four tested VISA strains, suggesting that the thickening of cell wall does not interfere with the effects of thioridazine. In S. epidermidis, no synergy was observed in all tested strains, suggesting that synergy by combining thioridazine and dicloxacillin is isolated to S. aureus species.
机译:我们之前已经证明,吩噻嗪(硫利达嗪)与β-内酰胺类抗生素双氯西林协同作用,杀死耐甲氧西林金黄色葡萄球菌。在这项研究中,我们研究了在万古霉素中间敏感金黄色葡萄球菌 (VISA) 和耐甲氧西林表皮葡萄球菌 (MRSE) 中是否也能观察到这两种药物的联合协同作用。在四种测试的VISA菌株中,有三种菌株观察到协同作用,表明细胞壁增厚不会干扰硫利达嗪的作用。在表皮葡萄球菌中,在所有测试菌株中均未观察到协同作用,这表明通过联合硫利达嗪和双氯西林的协同作用被分离到金黄色葡萄球菌物种中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号